A Phase 3 interventional study of Alpha-1 antitrypsin (AAT) and Placebo in Graft Versus Host Disease (GVHD), sponsored by CSL Behring. Completed at 25 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-07-28.
Sponsored by CSL Behring (part of CSL Limited) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 454 studies in Graft vs Host Disease with a site in United States — 50 open to participants now, 71 under way, 2 of them phase 3. Graft vs Host Disease · United States.
Among the 454 studies in Graft vs Host Disease with a site in United States, this one is the 36th largest by enrollment of the 389 interventional ones that give a count, is one of 16 that started in 2020, is one of 40 in phase 3, and was the 377th registered.
804 studies on the registry are indexed under Graft vs Host Disease; 149 are open to participants now.
Browse Graft vs Host Disease studies →50 of the 454 studies in Graft vs Host Disease with a site in United States are open now. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 7+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Regenerative Ocular Immunobiologics LLC · Sites in United States
Ages 18+
Northwell Health · Sites in United States
Ages 18+
Sawa Ito, MD · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 103 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 42 (41%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
454 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 145 · Phase 2 227 · Phase 3 48 · Phase 4 5
First in 1986; this study’s year is marked. 16 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 136 is above the median of 35 across 639 interventional studies indexed under Graft vs Host Disease.
Median enrollment 30 across the 389 interventional studies, 81 across the 43 observational. Of the 347 that completed or were terminated, 166 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
80 of 454 have an industry lead sponsor. The 10 most frequent:
This study is registered under CSL Behring, one of the names counted as CSL Limited. Under that name alone:
CSL Behring is the lead sponsor of 145 studies on the registry; 17 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 17 (71%) have results posted.
CSL Limited has 2 studies filed under Graft vs Host Disease — fewer than ten, so there is no comparison to draw.
21 of the studies in Graft vs Host Disease with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07776210Phase 3Regenerative Ocular Immunobiologics LLCStudy of d-MAPPS™ Ophthalmic Solution in Adults With Chronic Ocular Graft-Versus-Host Disease (oGVHD) | 2027-03-31 |
| NCT06649201Case Comprehensive Cancer CenterVulvovaginal Graft-versus-Host Disease: Diagnosis and Microbiome Evaluation | 2026-11 |
| NCT05675930Memorial Sloan Kettering Cancer CenterA Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant | 2026-12-22 |
| NCT04044365National Cancer Institute (NCI)Pediatric cGVHD Symptom Scale | 2026-12-31 |
| NCT03533816University of Kansas Medical CenterExpanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide | 2027-01 |
Add all 21 to your calendar (.ics) → With an account.
Among the 454 studies in Graft vs Host Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Study CSL964_5001 will investigate the efficacy of AAT with corticosteroids compared with corticosteroids alone as first line therapy for patients with high-risk acute GVHD
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Alpha-1 antitrypsin (AAT) is a lyophilized powder for intravenous administration
Biological: Alpha-1 antitrypsin (AAT)
Albumin solution administered intravenously
Drug: Placebo
AAT is a lyophilized product for intravenous administration
Also known as: Alpha-1 proteinase inhibitor (A1-P1)
Albumin solution administered intravenously
Overall Response Rate (ORR) to Acute Graft-versus-Host Disease (GVHD) Treatment
The overall response is defined as having a CR or PR at Day 28, along with: being alive, free of any next-line GVHD therapy, and free of escalation of prednisone-equivalent steroid dose to 2.5 milligrams per kilogram (mg/kg)/day or more. The percentage of participants with CR or PR is reported here. Wilson score confidence intervals (CIs) are reported here as a measure of dispersion. The CR was defined as a score of 0 for the GVHD staging in all evaluable organs. The PR was defined as an improvement in one or more organs involved with GVHD symptoms without progression in others. Acute GVHD was graded and assessed for response based on Harris (Mount Sinai Acute GVHD International Consortium \[MAGIC\]) criteria (stage 0, 1, 2, 3, 4) for skin, liver, upper gastrointestinal (GI) tract, and lower GI tract. Participants who had an escalation of prednisone-equivalent steroid dose to 2.5 mg/kg/day or higher were classified as non-responders (NR).
Time frame: At Day 28
Duration of Response (DOR)
The DOR was defined as time from the Day 28 response (CR or PR) until the first of the following events occurs: progression of acute GVHD, death, any next-line GVHD therapy, or escalation of prednisone-equivalent steroids to greater than or equal to (\>=) 2.5 mg/kg/day. Wald CIs are reported here as a measure of dispersion.
Time frame: Up to 12 months
Number of Participants With Non-relapse Mortality (NRM) Event
An event of NRM was death without prior evidence of relapse/progression of the primary disease, where relapse/progression was treated as a competing risk. Cumulative incidence of NRM at 6 and 12 months post-randomization is reported here for this outcome measure.
Time frame: At 6 and 12 months
Number of Overall and Progression-free Survival Events
An event for overall survival (OS) was death from any cause, while an event for progression-free survival (PFS) was death from any cause or relapse/progression of the primary disease.
Time frame: At 6 and 12 months
Number of Participants With GVHD-free Survival
GVHD-free survival was defined as participants being alive, free of acute or chronic GVHD, and free of any next-line GVHD therapy or escalation of steroids to \>=2.5 mg/kg/day prednisone or equivalent for treatment of GVHD.
Time frame: At Day 56
Percentage of Participants With Response
The percentage of participants with CR, PR (including subset with very good partial response \[VGPR\]), and treatment failure (TF). The designation of TF consisted of participants with NR, mixed response (MR) or progression. The initiation of additional systemic (next-line) GVHD therapies, escalation of prednisone equivalent steroid dose to \>= 2.5 mg/kg/day, or death from any cause prior to the assessment timepoint was also considered a TF. Simultaneous Goodman CIs are provided for category proportions for each arm at each assessment time.
Time frame: At Day 7, 14, 21, 28, 56, and 86
Percentage of Participants With Response Allowing for Approved Next-line Therapy
The percentage of participants with CR, PR (including subset with VGPR), and TF allowing for treatment with next-line therapy. The designation of TF consisted of participants with NR, MR, or progression. The escalation of prednisone-equivalent steroid dose to \>= 2.5 mg/kg/day or death from any cause prior to the assessment timepoint was also considered a TF. Simultaneous Goodman CIs are provided for category proportions for each arm at each assessment time.
Time frame: At Day 7, 14, 21, 28, 56, and 86
Incidence of Grade 2 to 3 Systemic Infections
The cumulative incidence of Grade 2 to 3 systemic infections. Grade 2 to 3 systemic infections were defined according to the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Manual of Procedures.
Time frame: Up to 90 days (including 30 days after last dose of study drug)
Percentage of Participants With Grade 3 to 5 Treatment-emergent Adverse Events (TEAEs)
The incidence of Grade 3 to 5 TEAEs (per Common Terminology Criteria for Adverse Events \[CTCAE\] Version 5.0). Wilson score CIs are reported here as a measure of dispersion.
Time frame: Up to 30 days after the last dose of study drug
Cumulative Incidence of Chronic GVHD
Chronic GVHD was defined per National Institutes of Health (NIH) Consensus Criteria. Diagnosis of chronic GVHD of any severity (mild, moderate, or severe) was considered an event for this outcome measure, where death before cGVHD was treated as a competing risk.
Time frame: At 6 and 12 months
Cumulative Incidence of Disease Relapse/ Progression of Primary Disease
The cumulative incidence of relapse/progression of the primary disease, with death prior to relapse/progression treated as a competing risk. Death without prior relapse/progression was treated as a competing risk for relapse/progression.
Time frame: At 6 months and 12 months
DOR - Supplementary Analysis
The DOR was defined as time from the Day 28 response (CR or PR) until the first of the following events occurs: death, any next-line GVHD therapy, or escalation of prednisone-equivalent steroids to \>= 2.5 mg/kg/day. Wald CIs are reported here as a measure of dispersion.
Time frame: Up to 12 months
This study was conducted at 26 investigative sites in the United States of America.
| Milestone | Alpha-1 Antitrypsin (AAT) | Placebo |
|---|---|---|
| Started | 65 | 71 |
| Treated | 63 | 69 |
| Completed | 38 | 41 |
| Not completed | 27 | 30 |
| Withdrew: Adverse event, not serious | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Participant decision | 2 | 4 |
| Withdrew: Physician decision | 3 | 2 |
| Withdrew: Death | 14 | 18 |
| Withdrew: Enrolled but treatment not administered | 2 | 0 |
| Withdrew: Multiple reasons for study discontinuation documented; including death, primary reason not reported | 3 | 1 |
| Withdrew: Multiple reasons for study discontinuation documented; excluding death, primary reason not reported | 2 | 4 |
The overall response is defined as having a CR or PR at Day 28, along with: being alive, free of any next-line GVHD therapy, and free of escalation of prednisone-equivalent steroid dose to 2.5 milligrams per kilogram (mg/kg)/day or more. The percentage of participants with CR or PR is reported here. Wilson score confidence intervals (CIs) are reported here as a measure of dispersion. The CR was defined as a score of 0 for the GVHD staging in all evaluable organs. The PR was defined as an improvement in one or more organs involved with GVHD symptoms without progression in others. Acute GVHD was graded and assessed for response based on Harris (Mount Sinai Acute GVHD International Consortium \[MAGIC\]) criteria (stage 0, 1, 2, 3, 4) for skin, liver, upper gastrointestinal (GI) tract, and lower GI tract. Participants who had an escalation of prednisone-equivalent steroid dose to 2.5 mg/kg/day or higher were classified as non-responders (NR).
| percentage of participants | Alpha-1 Antitrypsin (AAT) | Placebo |
|---|---|---|
| Overall Response Rate (ORR) to Acute Graft-versus-Host Disease (GVHD) Treatment | 60.0 (47.86 to 71.03) | 45.1 (34.05 to 56.60) |
The DOR was defined as time from the Day 28 response (CR or PR) until the first of the following events occurs: progression of acute GVHD, death, any next-line GVHD therapy, or escalation of prednisone-equivalent steroids to greater than or equal to (\>=) 2.5 mg/kg/day. Wald CIs are reported here as a measure of dispersion.
| days | Alpha-1 Antitrypsin (AAT) | Placebo |
|---|---|---|
| Duration of Response (DOR) | 82 (22 to 176) | 154 (57 to NA) |
An event of NRM was death without prior evidence of relapse/progression of the primary disease, where relapse/progression was treated as a competing risk. Cumulative incidence of NRM at 6 and 12 months post-randomization is reported here for this outcome measure.
| Participants | Alpha-1 Antitrypsin (AAT) | Placebo |
|---|---|---|
| At 6 months | 12 | 14 |
| At 12 months | 13 | 14 |
An event for overall survival (OS) was death from any cause, while an event for progression-free survival (PFS) was death from any cause or relapse/progression of the primary disease.
| events | Alpha-1 Antitrypsin (AAT) | Placebo |
|---|---|---|
| OS: At 6 months | 16 | 18 |
| OS: At 12 months | 20 | 23 |
| PFS: At 6 months | 25 | 28 |
| PFS: At 12 months | 27 | 29 |
GVHD-free survival was defined as participants being alive, free of acute or chronic GVHD, and free of any next-line GVHD therapy or escalation of steroids to \>=2.5 mg/kg/day prednisone or equivalent for treatment of GVHD.
| Participants | Alpha-1 Antitrypsin (AAT) | Placebo |
|---|---|---|
| Number of Participants With GVHD-free Survival | 29 | 25 |
The percentage of participants with CR, PR (including subset with very good partial response \[VGPR\]), and treatment failure (TF). The designation of TF consisted of participants with NR, mixed response (MR) or progression. The initiation of additional systemic (next-line) GVHD therapies, escalation of prednisone equivalent steroid dose to \>= 2.5 mg/kg/day, or death from any cause prior to the assessment timepoint was also considered a TF. Simultaneous Goodman CIs are provided for category proportions for each arm at each assessment time.
| percentage of participants | Alpha-1 Antitrypsin (AAT) | Placebo |
|---|---|---|
| At Day 7 - CR | 29.2 (17.86 to 43.97) | 33.8 (22.03 to 48.00) |
| At Day 7 - PR | 33.8 (21.62 to 48.69) | 25.4 (15.16 to 39.22) |
| At Day 7 - TF | 36.9 (24.20 to 51.76) | 40.8 (28.08 to 54.98) |
| At Day 14 - CR | 47.7 (33.66 to 62.10) | 46.5 (33.11 to 60.38) |
| At Day 14 - PR | 23.1 (13.07 to 37.45) | 14.1 (6.89 to 26.65) |
| At Day 14 - TF | 29.2 (17.86 to 43.97) | 39.4 (26.85 to 53.61) |
| At Day 21 - CR | 55.4 (40.79 to 69.10) | 40.8 (28.08 to 54.98) |
| At Day 21 - PR | 9.2 (3.66 to 21.41) | 9.9 (4.18 to 21.54) |
| At Day 21 - TF | 35.4 (22.91 to 50.23) | 49.3 (35.68 to 63.01) |
| At Day 28 - CR | 55.4 (40.79 to 69.10) | 40.8 (28.08 to 54.98) |
| At Day 28 - PR | 4.6 (1.28 to 15.31) | 4.2 (1.17 to 14.12) |
| At Day 28 - TF | 40.0 (26.84 to 54.78) | 54.9 (40.96 to 68.16) |
| At Day 56 - CR | 44.6 (30.90 to 59.21) | 35.2 (23.22 to 49.42) |
| At Day 56 - PR | 6.2 (2.00 to 17.41) | 4.2 (1.17 to 14.12) |
| At Day 56 - TF | 49.2 (35.06 to 63.52) | 60.6 (46.39 to 73.15) |
| At Day 86 - CR | 63.4 (44.82 to 78.72) | 50.0 (32.30 to 67.70) |
| At Day 86 - PR | 2.4 (0.32 to 16.22) | 10.0 (3.27 to 26.76) |
| At Day 86 - TF | 34.1 (19.37 to 52.81) | 40.0 (23.87 to 58.64) |
The percentage of participants with CR, PR (including subset with VGPR), and TF allowing for treatment with next-line therapy. The designation of TF consisted of participants with NR, MR, or progression. The escalation of prednisone-equivalent steroid dose to \>= 2.5 mg/kg/day or death from any cause prior to the assessment timepoint was also considered a TF. Simultaneous Goodman CIs are provided for category proportions for each arm at each assessment time.
| percentage of participants | Alpha-1 Antitrypsin (AAT) | Placebo |
|---|---|---|
| At Day 7 - CR | 29.2 (17.86 to 43.97) | 33.8 (22.03 to 48.00) |
| At Day 7 - PR | 36.9 (24.20 to 51.76) | 31.0 (19.69 to 45.12) |
| At Day 7 - TF | 33.8 (21.62 to 48.69) | 35.2 (23.22 to 49.42) |
| At Day 14 - CR | 50.8 (36.48 to 64.94) | 46.5 (33.11 to 60.38) |
| At Day 14 - PR | 29.2 (17.86 to 43.97) | 26.8 (16.27 to 40.72) |
| At Day 14 - TF | 20.0 (10.79 to 34.07) | 26.8 (16.27 to 40.72) |
| At Day 21 - CR | 56.9 (42.26 to 70.47) | 46.5 (33.11 to 60.38) |
| At Day 21 - PR | 15.4 (7.54 to 28.84) | 18.3 (9.85 to 31.51) |
| At Day 21 - TF | 27.7 (16.63 to 42.37) | 35.2 (23.22 to 49.42) |
| At Day 28 - CR | 63.1 (48.24 to 75.80) | 49.3 (35.68 to 63.01) |
| At Day 28 - PR | 9.2 (3.66 to 21.41) | 14.1 (6.89 to 26.65) |
| At Day 28 - TF | 27.7 (16.63 to 42.37) | 36.6 (24.41 to 50.82) |
| At Day 56 - CR | 52.3 (37.90 to 66.34) | 47.9 (34.39 to 61.70) |
| At Day 56 - PR | 13.8 (6.52 to 27.03) | 4.2 (1.17 to 14.12) |
| At Day 56 - TF | 33.8 (21.62 to 48.69) | 47.9 (34.39 to 61.70) |
| At Day 86 - CR | 65.9 (47.19 to 80.63) | 72.5 (53.62 to 85.74) |
| At Day 86 - PR | 7.3 (2.04 to 23.07) | 10.0 (3.27 to 26.76) |
| At Day 86 - TF | 26.8 (13.90 to 45.45) | 17.5 (7.52 to 35.63) |
The cumulative incidence of Grade 2 to 3 systemic infections. Grade 2 to 3 systemic infections were defined according to the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Manual of Procedures.
| events | Alpha-1 Antitrypsin (AAT) | Placebo |
|---|---|---|
| Incidence of Grade 2 to 3 Systemic Infections | 20 | 22 |
The incidence of Grade 3 to 5 TEAEs (per Common Terminology Criteria for Adverse Events \[CTCAE\] Version 5.0). Wilson score CIs are reported here as a measure of dispersion.
| percentage of participants | Alpha-1 Antitrypsin (AAT) | Placebo |
|---|---|---|
| Percentage of Participants With Grade 3 to 5 Treatment-emergent Adverse Events (TEAEs) | 46.0 (34.31 to 58.21) | 65.2 (53.45 to 75.38) |
Chronic GVHD was defined per National Institutes of Health (NIH) Consensus Criteria. Diagnosis of chronic GVHD of any severity (mild, moderate, or severe) was considered an event for this outcome measure, where death before cGVHD was treated as a competing risk.
| Participants | Alpha-1 Antitrypsin (AAT) | Placebo |
|---|---|---|
| At 6 months | 13 | 9 |
| At 12 months | 20 | 14 |
The cumulative incidence of relapse/progression of the primary disease, with death prior to relapse/progression treated as a competing risk. Death without prior relapse/progression was treated as a competing risk for relapse/progression.
| Participants | Alpha-1 Antitrypsin (AAT) | Placebo |
|---|---|---|
| At 6 months | 14 | 14 |
| At 12 months | 15 | 15 |
The DOR was defined as time from the Day 28 response (CR or PR) until the first of the following events occurs: death, any next-line GVHD therapy, or escalation of prednisone-equivalent steroids to \>= 2.5 mg/kg/day. Wald CIs are reported here as a measure of dispersion.
| days | Alpha-1 Antitrypsin (AAT) | Placebo |
|---|---|---|
| DOR - Supplementary Analysis | NA (85 to NA) | NA (109 to NA) |
The overall response is defined as having a CR or PR at Day 28, along with: being alive, free of any next-line GVHD therapy, and free of escalation of prednisone-equivalent steroid dose to 2.5 mg/kg/day or more. The percentage of participants with CR or PR based on gender subgroup is reported here. Clopper-Pearson CIs are reported here as a measure of dispersion. The CR was defined as a score of 0 for the GVHD staging in all evaluable organs. The PR was defined as an improvement in one or more organs involved with GVHD symptoms without progression in others. Acute GVHD was graded and assessed for response based on Harris (MAGIC) criteria (stage 0, 1, 2, 3, 4) for skin, liver, upper GI tract, and lower GI tract. Participants who had an escalation of prednisone-equivalent steroid dose to 2.5 mg/kg/day or higher were classified as NR.
| percentage of participants | Alpha-1 Antitrypsin (AAT) | Placebo |
|---|---|---|
| Male | 57.8 (42.15 to 72.34) | 46.2 (30.09 to 62.82) |
| Female | 65.0 (40.78 to 84.61) | 43.8 (26.36 to 62.34) |
The overall response is defined as having a CR or PR at Day 28, along with: being alive, free of any next-line GVHD therapy, and free of escalation of prednisone-equivalent steroid dose to 2.5 mg/kg/day or more. Percentage of participants with CR or PR based on race subgroup is reported here. Clopper-Pearson CIs are reported here as a measure of dispersion. The CR was defined as a score of 0 for the GVHD staging in all evaluable organs. The PR was defined as an improvement in one or more organs involved with GVHD symptoms without progression in others. Acute GVHD was graded and assessed for response based on Harris (MAGIC) criteria (stage 0, 1, 2, 3, 4) for skin, liver, upper GI tract, and lower GI tract. Participants who had an escalation of prednisone-equivalent steroid dose to 2.5 mg/kg/day or higher were classified as NR. The "Non-White" subgroup includes: American Indian/Alaska Native, Asian, Black or African American, Hawaiian/Pacific Islander, More than One Race, and Unknown.
| percentage of participants | Alpha-1 Antitrypsin (AAT) | Placebo |
|---|---|---|
| White | 58.8 (44.17 to 72.42) | 39.3 (27.07 to 52.69) |
| Non-white | 64.3 (35.14 to 87.24) | 80.0 (44.39 to 97.48) |
Collected over From randomization to 12 months (end of study [EOS] follow-up): AEs and Serious AEs (SAEs) reported from randomization until 30 days post last dose. Beginning at 31 days from the last dose of the study drug through the EOS follow-up, only SAEs related to the study drug and unanticipated SAEs (regardless of relationship) required reporting. All-cause mortality includes any deaths, regardless of the timing, including those reported beyond the 12 months, up to 16 months for the last reported death.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Alpha-1 Antitrypsin (AAT) | 21/65 (32.3%) | 11/63 (17.5%) | 37/63 (58.7%) |
| Placebo | 23/71 (32.4%) | 23/69 (33.3%) | 42/69 (60.9%) |
| Event | Alpha-1 Antitrypsin (AAT) | Placebo |
|---|---|---|
| FallInjury, poisoning and procedural complications | 0/63 | 4/69 |
| Oedema peripheralGeneral disorders | 2/63 | 0/69 |
| Small intestinal obstructionGastrointestinal disorders | 0/63 | 2/69 |
| Acute kidney injuryRenal and urinary disorders | 0/63 | 2/69 |
| Subdural haematomaInjury, poisoning and procedural complications | 1/63 | 0/69 |
| Intracranial massNervous system disorders | 1/63 | 0/69 |
| SyncopeNervous system disorders | 1/63 | 0/69 |
| Toxic encephalopathyNervous system disorders | 1/63 | 0/69 |
| DysphagiaGastrointestinal disorders | 1/63 | 0/69 |
| HypokalaemiaMetabolism and nutrition disorders | 1/63 | 0/69 |
| Event | Alpha-1 Antitrypsin (AAT) | Placebo |
|---|---|---|
| HyperglycaemiaMetabolism and nutrition disorders | 13/63 | 11/69 |
| Oedema peripheralGeneral disorders | 12/63 | 10/69 |
| HypocalcaemiaMetabolism and nutrition disorders | 7/63 | 12/69 |
| Alanine aminotransferase increasedInvestigations | 7/63 | 11/69 |
| HypomagnesaemiaMetabolism and nutrition disorders | 10/63 | 10/69 |
| HypertensionVascular disorders | 9/63 | 10/69 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 9/63 | 6/69 |
| Abdominal painGastrointestinal disorders | 9/63 | 6/69 |
| HyperkalaemiaMetabolism and nutrition disorders | 6/63 | 9/69 |
| HyponatraemiaMetabolism and nutrition disorders | 6/63 | 9/69 |
Analysis was performed on the intent-to-treat (ITT) population. The ITT population consisted of all randomized participants, classified according to their randomized treatment assignments. All randomized participants were included, regardless of whether the assigned study treatment was truly administered.
| Age, Continuous(years) | Alpha-1 Antitrypsin (AAT) | Placebo | Total |
|---|---|---|---|
| Mean | 56.6 ± 12.65 | 55.3 ± 13.75 | 55.9 ± 13.20 |
| Sex: Female, Male(Participants) | Alpha-1 Antitrypsin (AAT) | Placebo | Total |
|---|---|---|---|
| Female | 20 | 32 | 52 |
| Male | 45 | 39 | 84 |
| Ethnicity (NIH/OMB)(Participants) | Alpha-1 Antitrypsin (AAT) | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 8 | 3 | 11 |
| Not Hispanic or Latino | 56 | 66 | 122 |
| Unknown or Not Reported | 1 | 2 | 3 |
| Race (NIH/OMB)(Participants) | Alpha-1 Antitrypsin (AAT) | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 5 | 2 | 7 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 6 | 9 |
| White | 51 | 61 | 112 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 6 | 2 | 8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — CSL will consider on a case-by-case basis requests to share Individual Patient Data (IPD) with external bona-fide, qualified scientific and medical researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Requests for IPD will generally be considered once review by major regulatory authorities (ie FDA, EMA) is complete and the primary publication is available.
Access criteria: Proposed research should seek to answer a previously unanswered important medical or scientific question. Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD. If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.
Ran from Jan 2020 to primary completion in Sep 2023, 44 months.
Results were first posted in Aug 2025, 1 year 11 months after primary completion.
Of 31 phase 3 interventional studies under Graft vs Host Disease, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 48. This study's 44 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alpha 1-Antitrypsin